Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Multicenter Single-Arm Phase II Study Protocol | Zendy

Yoshihiro Miyasaka | Zendy; Takao Ohtsuka | Zendy; Susumu Eguchi | Zendy; Masafumi Inomata | Zendy; Kazuyoshi Nishihara | Zendy; Hiroyuki Shinchi | Zendy; Koji Okuda | Zendy; Hideo Baba | Zendy; Hiroaki Nagano | Zendy; Toshiharu Ueki | Zendy; Hirokazu Noshirο | Zendy; Masafumi Nakamura | Zendy

Open Access

Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Multicenter Single-Arm Phase II Study Protocol

Author(s) -

Yoshihiro Miyasaka,

Takao Ohtsuka,

Susumu Eguchi,

Masafumi Inomata,

Kazuyoshi Nishihara,

Hiroyuki Shinchi,

Koji Okuda,

Hideo Baba,

Hiroaki Nagano,

Toshiharu Ueki,

Hirokazu Noshirο,

Masafumi Nakamura

Publication year - 2021

Publication title -

international journal of surgery protocols

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.291

H-Index - 4

ISSN - 2468-3574

DOI - 10.29337/ijsp.142

Subject(s) - gemcitabine , medicine , regimen , pancreatic cancer , neoadjuvant therapy , oncology , chemotherapy , clinical endpoint , cancer , breast cancer , clinical trial

Although neoadjuvant treatment is recommended for patients with borderline resectable pancreatic cancer (BRPC), no standard neoadjuvant regimen has been established for BRPC with arterial involvement (BRPC-A), which is associated with a higher risk of margin-positive resection and poorer prognosis than BRPC with only venous involvement. Gemcitabine plus nab-paclitaxel (GnP) has been reported to significantly reduce tumor size in metastatic pancreatic cancer, and some retrospective studies suggested that neoadjuvant GnP for BRPC improved resectability and survival.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research